Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network Meta-Analysis of survival data

被引:15
作者
Chow, Ronald [1 ,2 ]
Simone, Charles B., II [2 ]
Jairam, Meghan Pooja [3 ]
Swaminath, Anand [4 ]
Boldt, Gabriel [5 ]
Lock, Michael [5 ]
机构
[1] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada
[2] Mem Sloan Kettering Canc Ctr, New York Proton Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Columbia Univ, Columbia Univ Vagelos Coll Phys & Surg, New York, NY USA
[4] McMaster Univ, Juravinski Canc Ctr, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[5] Univ Western Ontario, London Hlth Sci Ctr, Schulich Sch Med & Dent, London Reg Canc Program, London, ON, Canada
关键词
Hepatocellular carcinoma; radiofrequency ablation; radiation therapy; transarterial chemoembolization; transarterial radioembolization; Yttrium-90; systematic review; network meta-analysis; STEREOTACTIC BODY RADIOTHERAPY; STAGE HEPATOCELLULAR-CARCINOMA; ARTERIAL CHEMOEMBOLIZATION; EFFICACY; TRIAL; RADIOEMBOLIZATION; OUTCOMES;
D O I
10.1080/0284186X.2021.2009563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction The comparative effectiveness of radiofrequency ablation (RFA), radiation therapy (RT), transarterial chemoembolization (TACE) and transarterial radioembolization with Yttrium-90 (Y90) relative to one another for the treatment of hepatocellular carcinoma (HCC) is unclear. The aim of this systematic review and network meta-analysis is to compare RFA to RT to TACE to Y90 in the treatment of HCC. Methods Pubmed, Embase and Cochrane CENTRAL were searched up until April 19, 2021. Observational analyses with propensity score matched (PSM) cohort analyses and randomized controlled trials (RCT) reporting on two or more treatments relative to one another with respect to overall survival (OS) and/or progression free survival (PFS) were included. Survival data were extracted from Kaplan-Meier survival curves, and meta-analyzed using a multivariate network meta-analysis. Results After exclusions, 24 RCTs or PSM observational studies reporting on 5549 patients were included. While 1-year OS was greater for Y90 than TACE (RR 0.85, 95% CI: 0.72-0.99), all other 1-year OS comparisons across the 4 modalities yielded similar OS, and there were no differences across any modalities in 2-year and 3-year OS. TACE had a modest PFS advantage relative to RFA (RR 0.81, 95% CI: 0.68-0.95) and RT (RR 0.65, 95% CI: 0.51-0.83) at 2 years. Conclusion All modalities assessed resulted in similar OS, which explains the current heterogenous practice patterns. This conclusion may assist in decision making based on administrative and patient costs, and implementation of these modalities. Other factors such as toxicity rate specific to individual patients could not be assessed using network meta-analysis and may also play a role in selection of modality. Further studies, ideally using PSM cohort analyses or RCT study design, reporting on OS, PFS, local control, complete response and toxicity are needed prior to drawing definitive conclusions.
引用
收藏
页码:484 / 494
页数:11
相关论文
共 41 条
  • [1] Akinwande O, 2016, ANTICANCER RES, V36, P239
  • [2] [Anonymous], 2000, INT J CLIN ONCOL
  • [3] External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database
    Berger, Nicholas G.
    Tanious, Michael N.
    Hammad, Abdulrahman Y.
    Miura, John T.
    Mogal, Harveshp
    Clarke, Callisia N.
    Christians, Kathleen K.
    Tsai, Susan
    Gamblin, T. Clark
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2017, 116 (03) : 307 - 312
  • [4] Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
    Bettinger, Dominik
    Gkika, Eleni
    Schultheiss, Michael
    Glaser, Nicolas
    Lange, Sophie
    Maruschke, Lars
    Buettner, Nico
    Kirste, Simon
    Nestle, Ursula
    Grosu, Anca-Ligia
    Thimme, Robert
    Brunner, Thomas B.
    [J]. BMC CANCER, 2018, 18
  • [5] Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis
    Bush, David A.
    Smith, Jason C.
    Slater, Jerry D.
    Volk, Michael L.
    Reeves, Mark E.
    Cheng, Jason
    Grove, Roger
    de Vera, Michael E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (01): : 477 - 482
  • [6] RETRACTED: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm - A randomized controlled trial (Retracted article. See vol. 301, pg. 1931, 2009)
    Cheng, Bao-Quan
    Jia, Chong-Qi
    Liu, Chun-Tao
    Fan, Wei
    Wang, Qing-Liang
    Zhang, Zong-Li
    Yi, Cui-Hua
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (14): : 1669 - 1677
  • [7] Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis
    Chu, Hee Ho
    Kim, Jin Hyoung
    Yoon, Hyun-Ki
    Ko, Heung-Kyu
    Gwon, Dong Il
    Kim, Pyo Nyun
    Sung, Kyu-Bo
    Ko, Gi-Young
    Kim, So Yeon
    Park, Seong Ho
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (10) : 1533 - 1543
  • [8] Liver metastases and SBRT: A new paradigm?
    Comito, Tiziana
    Clerici, Elena
    Tozzi, Angelo
    D'Agostino, Giuseppe
    [J]. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2015, 20 (06) : 464 - 471
  • [9] Intermediate stage hepatocellular carcinoma: a summary review
    Elshaarawy, Omar
    Gomaa, Asmaa
    Omar, Hazem
    Rewisha, Eman
    Waked, Imam
    [J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2019, 6 : 105 - 117
  • [10] Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies
    Eriguchi, Takahisa
    Takeda, Atsuya
    Tateishi, Yudai
    Tsurugai, Yuichiro
    Sanuki, Naoko
    Ebinuma, Hirotoshi
    Horita, Nobuyuki
    [J]. HEPATOLOGY RESEARCH, 2021, 51 (07) : 813 - 822